Drugs / METR-NK cell
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07096583 | Jul 2025 → Jul 2026 overdue | ovarian cancer | Anhui Provincial Cancer Hospital | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT06395844 | May 2024 → May 2025 overdue | ovarian carcinoma | Anhui Provincial Cancer Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | METR-NK cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06395844 ↗ |
| Known as | metabolic remodeling nature killer cells | “METR-NK cell（metabolic remodeling nature killer cells）” NCT07096583 ↗1“METR-NK cell(Metabolic Remodeling Nature Killer Cells)” NCT06395844 ↗ |
| Route | Other | “Intraperitoneal allogeneic METR-NK cells infusion” NCT06395844 ↗ |